SHERIDAN, WYOMING – June 10, 2025 – Ecolab Life Sciences has opened a new Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania, signaling a major expansion of its technical capabilities in the North American biopharma market. Strategically located in a region dense with pharmaceutical operations, the new facility strengthens Ecolab’s position as a global technical partner for biopharmaceutical and contract manufacturing organizations.
Enhancing Process Development Capabilities for Biopharma
Purpose-built to support the purification of biotherapeutic molecules, the lab is equipped to provide comprehensive technical and applications support across the full product lifecycle. From early-stage development to commercial production, the facility helps biopharma firms streamline purification processes while improving regulatory readiness and cost-efficiency.
- High-throughput process development tools and manufacturing-scale chromatography columns
- Resin characterization capabilities to reduce cost of goods and enhance yield
- Support for regulatory submission packages with detailed data output
“Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world,” said Jennifer Sorrells, Ph.D., vice president of research and development, Ecolab Life Sciences. “This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab’s innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market."
Accelerating Time to Market Through Lifecycle Studies
The new lab is already in use by pharmaceutical manufacturers and CDMOs, enabling them to enhance production efficiency and shorten development timelines. Lifecycle studies can be launched and completed within weeks, offering customers speed, operational visibility, and full access to data and bench-level activities.
This rapid development support aligns with market demands for faster biologics commercialization cycles, particularly as the industry responds to growing therapeutic complexity and pipeline expansion. The ability to conduct iterative resin screening and downstream process optimization gives manufacturers a critical advantage in scaling robust and compliant processes.
Part of Ecolab’s Global Pharma Innovation Network
The Pennsylvania facility complements Ecolab’s European Applications and R&D Lab in Wales, U.K., forming a transatlantic network of innovation hubs under the Ecolab Life Sciences Pharma Center of Excellence. This multimillion-dollar initiative also includes:
- The Xchange, an interactive customer learning and collaboration space
- Active Pharmaceutical Ingredient (API) and excipient manufacturing capabilities
- Expanded R&D investment to support emerging bioprocessing trends
By combining R&D, technical support, and experiential engagement, Ecolab delivers a 360-degree approach to partnering with biopharma customers worldwide.
Strategic Value in a Competitive Bioprocessing Landscape
As biopharmaceutical companies face increasing pressure to accelerate product development while maintaining regulatory compliance and cost control, Ecolab’s new lab reinforces its ability to provide end-to-end support. The investment also reflects broader industry trends toward vertically integrated, partner-enabled innovation strategies.
Learn more here.